Discover Oncology (Feb 2024)

PLCD3 inhibits apoptosis and promotes proliferation, invasion and migration in gastric cancer

  • Yantao Yu,
  • Shantanu Baral,
  • Qiannan Sun,
  • Jianyue Ding,
  • Qi Zhang,
  • Fanyu Zhao,
  • Shuyang Gao,
  • Qing Yao,
  • Haoyue Yu,
  • Bin Liu,
  • Daorong Wang

DOI
https://doi.org/10.1007/s12672-024-00881-w
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Gastric cancer (GC) is a heterogeneous disease whose development is accompanied by alterations in a variety of pathogenic genes. The phospholipase C Delta 3 enzyme is a member of the phospholipase C family, which controls substance transport between cells in the body. However, its role in gastric cancer has not been discovered. The purpose of this study was to investigate the expression and mechanism of action of PLCD3 in connection to gastric cancer. By Western blot analysis and immunohistochemistry, PLCD3 mRNA and protein expression levels were measured, with high PLCD3 expression suggesting poor prognosis. In N87 and HGC-27 cells, the silencing of PLCD3 using small interfering RNA effectively induced apoptosis and inhibited tumor cell proliferation, invasion, and migration. Conversely, overexpression of PLCD3 using overexpressed plasmids inhibited apoptosis in AGS and BGC-823 cells and promoted proliferation, migration, and invasion. In order to investigate the underlying mechanisms, we conducted further analysis of PLCD3, which indicates that this protein is closely related to the cell cycle and EMT. Additionally, we found that overexpression of PLCD3 inhibits apoptosis and promotes the development of GC cells through JAK2/STAT3 signaling. In conclusion, PLCD3 inhibits apoptosis and promotes proliferation, invasion, and migration, which indicated that PLCD3 might serve as a therapeutic target for gastric cancer.